Argos Therapeutics (ARGS) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Argos Therapeutics (ARGS) PT Cut to $11 at Piper Jaffray; 'Overweight' Maintained on Increased 2016 Visibility
November 17, 2015 6:40 AM ESTPiper Jaffray analyst Charles Duncan lowered his price target on Argos Therapeutics (NASDAQ: ARGS) to $11.00 (from $20.00) following Q3 results but maintained an Overweight rating saying Phase 3 interims and near term trial starts should yield increased 2016 visibility.
Duncan commented, "Monday morning Argos announced 3Q... More
